Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

NCT02221960 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02221960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02221960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
September 15, 2014
Completion date
July 3, 2017
Enrollment
39 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic solid tumors